{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:59:24Z","timestamp":1760014764811},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.diagmicrobio.2013.10.020","type":"journal-article","created":{"date-parts":[[2013,11,6]],"date-time":"2013-11-06T02:46:40Z","timestamp":1383706000000},"page":"437-442","source":"Crossref","is-referenced-by-count":13,"title":["Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE program, 2009\u20132011"],"prefix":"10.1016","volume":"78","author":[{"given":"Robert K.","family":"Flamm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 4","key":"10.1016\/j.diagmicrobio.2013.10.020_bb0005","first-page":"iv9","article-title":"Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity","volume":"65","author":"Biek","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2013.10.020_bb0130","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: ninth edition, M07-A9","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"10.1016\/j.diagmicrobio.2013.10.020_bb0135","series-title":"Performance standards for antimicrobial susceptibility testing: 23rd informational supplement (M100-S23)","author":"Clinical and Laboratory Standards Institute","year":"2013"},{"issue":"Suppl 3","key":"10.1016\/j.diagmicrobio.2013.10.020_bb0140","first-page":"iii45","article-title":"Review of ceftaroline fosamil microbiology: integrated FOCUS studies","volume":"66","author":"Critchley","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.diagmicrobio.2013.10.020_bb0025","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1093\/cid\/cis563","article-title":"In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE surveillance program (2008\u20132010)","volume":"55","author":"Farrell","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.diagmicrobio.2013.10.020_bb0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1469-0691.2006.01395.x","article-title":"Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia","volume":"12","author":"File","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2013.10.020_bb0035","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3810\/pgm.2010.03.2130","article-title":"Burden of community-acquired pneumonia in North American adults","volume":"122","author":"File","year":"2010","journal-title":"Postgrad Med"},{"key":"10.1016\/j.diagmicrobio.2013.10.020_bb0040","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1128\/AAC.00330-12","article-title":"Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program","volume":"56","author":"Flamm","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2013.10.020_bb0045","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1128\/AAC.01797-09","article-title":"Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States","volume":"54","author":"Jacobs","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2013.10.020_bb0050","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.diagmicrobio.2010.08.024","article-title":"Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998\u20132009)","volume":"68","author":"Jones","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.diagmicrobio.2013.10.020_bb0055","first-page":"iii69","article-title":"Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study","volume":"66","author":"Jones","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2013.10.020_bb0060","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1128\/AAC.01787-10","article-title":"In vitro activity of ceftaroline against Gram-positive and Gram-negative pathogens isolated from patients attending Canadian hospitals in 2009","volume":"55","author":"Karlowsky","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2013.10.020_bb0065","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1378\/chest.128.6.3854","article-title":"Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia","volume":"128","author":"Kollef","year":"2005","journal-title":"Chest"},{"issue":"Suppl 3","key":"10.1016\/j.diagmicrobio.2013.10.020_bb0070","first-page":"iii11","article-title":"Ceftaroline fosamil: a new broad-spectrum cephalosporin","volume":"66","author":"Laudano","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2013.10.020_bb0075","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1128\/AAC.01324-08","article-title":"In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae","volume":"53","author":"McGee","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2013.10.020_bb0080","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/jac\/dks038","article-title":"Activity of ceftaroline against serotyped Streptococcus pneumoniae isolates from Europe and South Africa associated with community-acquired bacterial pneumonia (2007\u201308)","volume":"67","author":"Morrissey","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.diagmicrobio.2013.10.020_bb0085","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1093\/cid\/cis561","article-title":"AWARE ceftaroline surveillance program (2008\u20132010); trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States","volume":"55","author":"Pfaller","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2013.10.020_bb0090","doi-asserted-by":"crossref","first-page":"iii53","DOI":"10.1093\/jac\/dkr099","article-title":"Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia","volume":"66","author":"Rank","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.diagmicrobio.2013.10.020_bb0095","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1093\/cid\/cis560","article-title":"Activity analyses of staphylococcal isolates from pediatric, adult and elderly patients; AWARE ceftaroline surveillance program","volume":"55","author":"Sader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2013.10.020_bb0100","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1128\/AAC.01516-09","article-title":"In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates","volume":"54","author":"Saravolatz","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2013.10.020_bb0145","author":"Teflaro\u00ae Package Insert"},{"key":"10.1016\/j.diagmicrobio.2013.10.020_bb0110","author":"Tygacil Package Insert"},{"key":"10.1016\/j.diagmicrobio.2013.10.020_bb0115","series-title":"Manual of clinical microbiology","author":"Versalovic","year":"2011"},{"key":"10.1016\/j.diagmicrobio.2013.10.020_bb0120","author":"VIBATIV Package Insert"},{"key":"10.1016\/j.diagmicrobio.2013.10.020_bb0125","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijantimicag.2010.02.006","article-title":"In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates","volume":"35","author":"Vidaillac","year":"2010","journal-title":"Int J Antimicrob Agents"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889313005828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889313005828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T01:25:29Z","timestamp":1539221129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889313005828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0732889313005828"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2013.10.020","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}